OptimizeRx’s (OPRX) “Buy” Rating Reiterated at Roth Mkm

OptimizeRx (NASDAQ:OPRX)‘s stock had its “buy” rating reissued by equities research analysts at Roth Mkm in a report issued on Thursday,Benzinga reports. They presently have a $16.00 price target on the stock, down from their prior price target of $20.00. Roth Mkm’s price objective points to a potential upside of 262.81% from the stock’s previous close.

Several other equities analysts have also recently weighed in on OPRX. Barclays cut their price objective on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday. Royal Bank of Canada cut their price target on OptimizeRx from $17.00 to $14.00 and set an “outperform” rating for the company in a report on Friday, August 16th. Stifel Nicolaus lowered their price objective on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday. B. Riley began coverage on shares of OptimizeRx in a research note on Thursday, July 25th. They set a “buy” rating and a $18.50 target price for the company. Finally, JMP Securities dropped their price objective on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a report on Thursday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.58.

OptimizeRx Stock Down 28.3 %

OPRX traded down $1.74 during midday trading on Thursday, hitting $4.41. 538,045 shares of the company’s stock traded hands, compared to its average volume of 134,035. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.07 and a quick ratio of 3.07. The company has a market cap of $80.80 million, a PE ratio of -4.41 and a beta of 1.32. The stock’s fifty day simple moving average is $6.75 and its 200-day simple moving average is $9.07. OptimizeRx has a one year low of $4.27 and a one year high of $16.65.

Institutional Investors Weigh In On OptimizeRx

Institutional investors have recently added to or reduced their stakes in the stock. Summit Securities Group LLC acquired a new stake in OptimizeRx in the 2nd quarter valued at $25,000. BNP Paribas Financial Markets lifted its holdings in shares of OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after acquiring an additional 2,414 shares during the period. Quest Partners LLC boosted its stake in shares of OptimizeRx by 15,965.6% in the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after purchasing an additional 9,739 shares in the last quarter. Connors Investor Services Inc. grew its holdings in shares of OptimizeRx by 15.1% in the 2nd quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock worth $191,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of OptimizeRx during the 2nd quarter worth about $282,000. 76.47% of the stock is owned by institutional investors and hedge funds.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.